Management of brain metastases in non-small cell lung cancer in the era of tyrosine kinase inhibitors

Lung cancer represents the most common cause of brain dissemination. Brain metastases are present at diagnosis in approximately 25% of patients with advanced non-small lung cancer (NSCLC) and may develop in a higher proportion during the course of the disease [1]. In two-thirds of lung cancer patients brain metastases are multiple, and in one third singular [2]. The incidence of leptomeningeal carcinomatosis in NSCLC ranges between 5 to 10% [3]. With better extracranial control resulting from the progress in systemic therapy, brain involvement is diagnosed more often.
Source: Cancer Treatment Reviews - Category: Cancer & Oncology Authors: Tags: Anti-Tumour Treatment Source Type: research